Dr. Andre A. Konski
Claim this profileChester County Hospital
Studies Prostate Adenocarcinoma
Studies Prostate Cancer
5 reported clinical trials
18 drugs studied
Affiliated Hospitals
Clinical Trials Andre A. Konski is currently running
Hormone + Radiation Therapy
for Prostate Cancer
This phase III trial compares less intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in treating patients with high risk prostate cancer and low gene risk score. This trial also compares more intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in patients with high risk prostate cancer and high gene risk score. Apalutamide may help fight prostate cancer by blocking the use of androgen by the tumor cells. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Giving a shorter hormone therapy treatment may work the same at controlling prostate cancer compared to the usual 24 month hormone therapy treatment in patients with low gene risk score. Adding apalutamide to the usual treatment may increase the length of time without prostate cancer spreading as compared to the usual treatment in patients with high gene risk score.
Recruiting2 awards Phase 36 criteria
Apalutamide + Hormone and Radiation Therapies
for Prostate Cancer
This phase III trial studies whether adding apalutamide to the usual treatment improves outcome in patients with lymph node positive prostate cancer after surgery. Radiation therapy uses high energy x-ray to kill tumor cells and shrink tumors. Androgens, or male sex hormones, can cause the growth of prostate cancer cells. Drugs, such as apalutamide, may help stop or reduce the growth of prostate cancer cell growth by blocking the attachment of androgen to its receptors on cancer cells, a mechanism similar to stopping the entrance of a key into its lock. Adding apalutamide to the usual hormone therapy and radiation therapy after surgery may stabilize prostate cancer and prevent it from spreading and extend time without disease spreading compared to the usual approach.
Recruiting2 awards Phase 3
More about Andre A. Konski
Clinical Trial Related3 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Andre A. Konski has experience with
- Apalutamide
- Histrelin
- Bicalutamide
- Leuprolide
- Triptorelin
- Goserelin
Breakdown of trials Andre A. Konski has run
Prostate Adenocarcinoma
Prostate Cancer
Breast Cancer
Pancreatic Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Andre A. Konski specialize in?
Andre A. Konski focuses on Prostate Adenocarcinoma and Prostate Cancer. In particular, much of their work with Prostate Adenocarcinoma has involved treating patients, or patients who are undergoing treatment.
Is Andre A. Konski currently recruiting for clinical trials?
Yes, Andre A. Konski is currently recruiting for 4 clinical trials in West Chester Pennsylvania. If you're interested in participating, you should apply.
Are there any treatments that Andre A. Konski has studied deeply?
Yes, Andre A. Konski has studied treatments such as Apalutamide, Histrelin, Bicalutamide.
What is the best way to schedule an appointment with Andre A. Konski?
Apply for one of the trials that Andre A. Konski is conducting.
What is the office address of Andre A. Konski?
The office of Andre A. Konski is located at: Chester County Hospital, West Chester, Pennsylvania 19380 United States. This is the address for their practice at the Chester County Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.